Medicare

Ovation Science Sees Expanded Opportunities for Its Topical Products Following U.S. Cannabis Rescheduling

VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / December 22, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC PINK:OVATF) ("Ovation"…

3 weeks ago

Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season

Telehealth Platform Offers Compounded GLP-1 Injections and Oral Tablets at $299/Month With No Contract as 100,000+ Patients Seek Affordable Semaglutide…

3 weeks ago

HCAP Partners Announces Investment in Puzzle Healthcare

Investment to accelerate the growth of a post-acute care platform focused on reducing hospital readmissions and improving outcomesSAN DIEGO, Dec.…

4 weeks ago

Glass House Brands Applauds Cannabis Reform Action

LONG BEACH, Calif. and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")…

4 weeks ago

NHI Announces $89.2 Million in Investments and Updates Pipeline

MURFREESBORO, TN / ACCESS Newswire / December 18, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that it has…

4 weeks ago

RXNT Announces TEFCA Connectivity and Integrated QHIN Access Through Strategic Partnership with Kno2

ANNAPOLIS, Md. and BOISE, Idaho, Dec. 18, 2025 /PRNewswire/ -- RXNT, a leading clinical EHR and Practice Management software company,…

4 weeks ago

RXNT Announces TEFCA Connectivity and Integrated QHIN Access Through Strategic Partnership with Kno2

ANNAPOLIS, Md. and BOISE, Idaho, Dec. 18, 2025 /PRNewswire/ -- RXNT, a leading clinical EHR and Practice Management software company,…

4 weeks ago

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

DefenCath® demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSIBERKELEY HEIGHTS, N.J., Dec. 18, 2025…

4 weeks ago

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

DefenCath® demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSIBERKELEY HEIGHTS, N.J., Dec. 18, 2025…

4 weeks ago

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority…

4 weeks ago